Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ND0612
- Development stage
- Phase 3
- Lead developer
- NeuroDerm
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
ND0612 is an investigational drug-device combination therapy designed for the treatment of motor fluctuations in Parkinson's disease patients. It delivers a continuous 24-hour subcutaneous infusion of liquid levodopa/carbidopa via a pump system. This novel approach aims to overcome the limitations of oral levodopa/carbidopa treatments by avoiding gastric involvement, providing increased bioavailability, and reducing variability of levodopa/carbidopa plasma levels. By maintaining stable and continuous therapeutic levodopa plasma concentrations, ND0612 has demonstrated significant improvement in "ON" time without troublesome dyskinesia and reduction in "OFF" time compared to oral immediate-release levodopa/carbidopa in clinical trials. The therapy is being developed by NeuroDerm Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation.
- Other names
- ND0612 high-doseND-0612 high-doseND 0612 high-dose
02
Targets
DRD2 (Dopamine D2 Receptor)DRD1 (Dopamine D1 Receptor)DDC (Aromatic L-amino acid decarboxylase)
Beyond the preview
Go deeper on ND0612.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ND0612.